Conference Interview #6 of 12
Antimicrobial resistance: A threat to modern medicine
Sarah Anwar, MDLinx
Iselin, New Jersey, United States | November 13-14, 2017
According to Dr. Weiss, resistance was previously isolated to certain geographic areas based on antibiotic usage, but has since spread globally. Unfortunately, antimicrobial resistance has become a threat to modern medicine. As pathogens gain resistance to antibiotics, once-treatable infections may result in mortality, as in the pre-antibiotic age. Misuse and overuse of antibiotics are among the leading factors that drive resistance.
Dr. Weiss concluded his interview by sharing estimates from recent reports.
“By 2050 there’ll be 10 million people dying or more of bacterial infections,” he stressed.
This begs the question, is it beneficial for patients to continue taking antibiotics even after they have gotten better? Or, will this drive resistance?
From this Conference
-
0:33Developing new antibioticsIselin, NJ, November 13, 2017--The development of new antibiotics is paramount to the functioning of modern medicine as we know it, said John H. Rex, MD, FACP, chief medical...
John H. Rex, MD, FACP -
0:49Biofilms contribute to the development of hospital-acquired infectionIselin, NJ, November 14, 2017--Polymicrobial biofilm allows for horizontal gene transfer and the development of new multi-drug resistant strains of bacteria, but the role of...
Carl Genberg, BSc, JD, CEO -
4:27Indwelling medical devices cause the majority of hospital-acquired infectionsIselin, NJ, November 14, 2017--About 70% of all hospital-acquired infections are due to the use of indwelling medical devices, and roughly 5% to 10% of hospitalized...
Carl Genberg, BSc, JD, CEO -
3:39Antibiotic resistance: The fate of all antibiotic monotherapiesIselin, NJ, November 13, 2017--Is antibiotic resistance the fate of all antibiotic monotherapies?
John H. Rex, MD, FACP -
0:29Proper infection control measures can reduce hospital-acquired infectionsIselin, NJ, November 14, 2017--Each year, approximately 1.7 million hospital-acquired infections occur, and 70% of these are related to the use of indwellling medical devices....
Carl Genberg, BSc, JD, CEO -
1:12Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)Iselin, NJ, November 13, 2017--CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is a public/private partnership between Wellcome Trust and the US...
John H. Rex, MD, FACP
This activity is neither sanctioned by, nor a part of the SMi group's annual meeting.
